Related Experiment Videos
Extent of surgery for differentiated thyroid cancer
Alan P B Dackiw1, Martha Zeiger
1Division of Endocrine and Oncologic Surgery, Department of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, MD 21287 USA. adackiw1@jhmi.edu
The Surgical Clinics of North America
|May 18, 2004
Summary
Total thyroidectomy with radioactive iodine (131I) ablation and thyroid hormone suppression is recommended for differentiated thyroid cancer. This approach reduces recurrence and mortality, improving patient prognosis.
Area of Science:
- Endocrinology
- Oncology
- Surgical Oncology
Background:
- Differentiated thyroid cancer management involves surgical intervention and adjuvant therapies.
- Optimizing treatment strategies is crucial for reducing disease recurrence and improving patient survival.
Purpose of the Study:
- To recommend total or near-total thyroidectomy followed by radioactive iodine (131I) ablation and thyroid hormone suppression therapy for differentiated thyroid cancer.
- To summarize decision analyses supporting this treatment approach.
Main Methods:
- Retrospective data analysis evaluating the efficacy of total thyroidectomy plus 131I and TSH suppression.
- Review of recent decision analyses supporting the recommended treatment regimen.
Main Results:
- Total thyroidectomy plus 131I and TSH suppression demonstrated reduced disease recurrence and mortality.
- This regimen effectively removes intrathyroidal cancer and aids in recurrence monitoring via 131I scans and thyroglobulin measurements.
Conclusions:
- The recommended treatment for differentiated thyroid cancer is total or near-total thyroidectomy with 131I ablation and TSH suppression.
- Safe surgical execution with a low complication rate is essential for this approach.
- This comprehensive treatment strategy offers an excellent prognosis for most patients with differentiated thyroid cancer.